MGMT methylation: A marker of response to temozolomide in low‐grade gliomas
2006; Wiley; Volume: 60; Issue: 6 Linguagem: Inglês
10.1002/ana.21044
ISSN1531-8249
AutoresSibille Everhard, Gentian Kaloshi, Emmanuelle Crinière, Alexandra Benouaich‐Amiel, Julie Lejeune, Yannick Marie, Marc Sanson, M. Kujas, Karima Mokhtari, Khê Hoang‐Xuan, Jean‐Yves Delattre, Joëlle Thillet,
Tópico(s)Brain Metastases and Treatment
ResumoAbstract The methylation status of the O6‐methylguanine‐methyltransferase promoter (MGMTP) was evaluated in 68 low‐grade gliomas treated by neoadjuvant temozolomide. Methylated MGMTP was detected in 63 of 68 (92.6 %) patients and was a favorable predictor of progression‐free survival as compared with unmethylated MGMTP tumors ( p < 0.0001). Assessment of MGMTP status could help identifying low‐grade gliomas patients more likely to respond to chemotherapy or to benefit from MGMT depletion strategies. Ann Neurol 2006;60:740–743
Referência(s)